Edition:
United States

Novo Nordisk A/S (NVO)

NVO on New York Consolidated

50.44USD
23 Oct 2017
Change (% chg)

$-0.10 (-0.21%)
Prev Close
$50.55
Open
$50.34
Day's High
$50.53
Day's Low
$50.21
Volume
880,469
Avg. Vol
1,900,134
52-wk High
$50.95
52-wk Low
$30.89

Summary

Name Age Since Current Position

Goran Ando

68 2013 Chairman of the Board

Lars Fruergaard Joergensen

50 2017 President, Chief Executive Officer

Jeppe Christiansen

57 2013 Vice Chairman of the Board

Jesper Brandgaard

53 2000 Chief Financial Officer, Executive Vice President

Maziar Doustdar

46 2015 Executive Vice President, International Operations

Mads Krogsgaard Thomsen

56 2000 Chief Science Officer, Executive Vice President

Doug Langa

2017 Executive Vice President, North America Operations

Camilla Sylvest

2017 Executive Vice President, Commercial Strategy & Corporate Affairs

Henrik Wulff

46 2015 Executive Vice President, Product Supply

Liselotte Hyveled

51 2014 Director, Employee Representative

Kasim Kutay

2017 Director

Anne Kverneland

60 2000 Director, Employee Representative

Helge Lund

52 2017 Director

Stig Stroebaek

53 1998 Director, Employee Representative

Soeren Thuesen Pedersen

52 2006 Director, Employee Representative

Brian Daniels

58 2016 Independent Director

Sylvie Gregoire

55 2015 Independent Director

Liz Hewitt

60 2012 Independent Director

Peter Hugreffe Ankersen

2015 Corporate Vice President & Head of Investor Relations

Biographies

Name Description

Goran Ando

Dr. Goran A. Ando, M.D. has served as Chairman of the Board of Directors of Novo Nordisk A/S since March 20, 2013. He was Vice Chairman of the Company's Board from March 8, 2006 until March 20, 2013, and he has been Member of the Board of the Company since March 9, 2005. He has been Chairman of the Nomination Committee of the Company since April 2013 and he is Chairman of the Research & Development Committee. He was Chief Executive Officer (CEO) of Celltech Group plc in the United Kingdom until 2004. He joined Celltech from Pharmacia (currently Pfizer) where he was Executive Vice President and President of Research and Development with additional responsibilities for manufacturing, Information Technology, business development and Mergers & Acquisitions from 1995 to 2003. From 1989 to 1995, he was Medical Director, moving to Deputy Research and Development Director, and then Research and Development Director of Glaxo Group in the United Kingdom. He was also Member of the Glaxo Group Executive Committee. He is Specialist in General Medicine and Founding Fellow of the American College of Rheumatology in the United States. He serves as Chairman of the Board of Directors of Symphogen A/S and as Member of the Boards of Novo A/S, Molecular Partners AG, EUSA Pharma Ltd. and ICMEC. He also serves as Senior Advisor to Essex Woodlands Health Ventures Ltd. in the United Kingdom. He has qualifications and executive background within the international pharmaceutical industry. He qualified as Medical Doctor at Linkopings Universitet (the University of Linkoping) in 1973, and as Specialist in General Medicine at the same institution in 1978.

Lars Fruergaard Joergensen

Mr. Lars Fruergaard Joergensen has been appointed President and Chief Executive Officer of Novo Nordisk A/S effective as of January 1, 2017. He has previously served as Executive Vice President and Chief of Staff of Novo Nordisk A/S since November 24, 2014. He was Executive Vice President for Information Technology, Quality & Corporate Development of the Company from January 31, 2013 until November 24, 2014. He joined Novo Nordisk in 1991 as Economist in Health Care, Economy and Planning and has over the years completed overseas postings in the United States and Japan. In 2004, he was appointed Senior Vice President for IT (Information Technology) and Corporate Development. He is Chairman of the Board of NNE A/S. He holds a Master of Science degree in Finance and Business Administration from Aarhus School of Business, Aarhus University (Aarhus Universitet), Denmark, from 1991.

Jeppe Christiansen

Mr. Jeppe Christiansen has been Vice Chairman of the Board of Directors of Novo Nordisk A/S since March 20, 2013. He is Chairman of the Remuneration Committee of the Company. He has been Chief Executive Officer of Fondsmaeglerselskabet Maj Invest A/S, Denmark, since 2009. He is also CEO of Maj Invest Holding A/S and Emlika ApS, as well as Member of the executive management of Maj Invest Equity A/S. He was Chief Executive Officer of LD Pensions from 2005 until 2009. Prior to that, he was Executive Director in Danske Bank from 1999 until 2004 with responsibility for group equity business and corporate international banking. From 1988 until 1999 he worked for LD Pensions, first as fund manager and later as deputy director with responsibility for the equity business. He is a Member of the Boards of Novo A/S, KIRKBI A/S and Symphogen A/S, as well as Chairman of the Board of Haldor Topsoee A/S, Vice Chairman of Maj Bank A/S and Member of the board of governors of Det Kgl. Vajsenhus. He has background and experience within the financial sector, in particular in relation to financial and capital market issues, as well as insight into the investor perspective. He has a Master of Science in Economics from the University of Copenhagen (Koebenhavns universitet), Denmark, from 1985.

Jesper Brandgaard

Mr. Jesper Brandgaard has served as Chief Financial Officer (CFO) and Executive Vice President at Novo Nordisk A/S since November 2000. He joined the Company in 1999 as Senior Vice President of Corporate Finance. He serves as Chairman of the Boards of Directors at SimCorp A/S and NNIT A/S, both in Denmark. He holds a Master of Science degree in Economics and Auditing from 1990, as well as a Master of Business Administration degree from 1995, both from the Copenhagen Business School in Denmark.

Maziar Doustdar

Mr. Maziar Mike Doustdar has been Executive Vice President, International Operations at Novo Nordisk A/S since April 2015. Maziar Mike Doustdar joined Novo Nordisk in 1992 as an office clerk in Vienna, Austria. He was appointed senior vice president of International Operations in 2013. In September 2016, he assumed additional geographical responsibility and was promoted to executive vice president of an expanded International Operations.

Mads Krogsgaard Thomsen

Mr. Mads Krogsgaard Thomsen has served as Chief Science Officer (CSO) and Executive Vice President at Novo Nordisk A/S since November 2000. He joined the Company in 1991 as Head of Growth Hormone Research. He was appointed Senior Vice President of Diabetes Research & Development in 1994. He has chaired Danish Research Council programs within endocrinology, and has served as President of the National Academy of Technical Sciences (ATV), Denmark. He sits on the Editorial Boards of international peer-reviewed journals and is Vice Chair of the Board of Directors of University of Copenhagen, Denmark. He obtained a DMV degree in Veterinary Medicine from Koebenhavns Universitet in 1986, where he also obtained a Doctorate of Philosophy degree in 1989, and a Doctorate of Science degree in 1991. In 2000 he became Adjunct Professor of Pharmacology at the Royal Veterinary and Agricultural University (currently the Faculty of Health and Medical Sciences of the University of Copenhagen), Denmark.

Doug Langa

Mr. Doug Langa has been Executive Vice President, North America Operations at Novo Nordisk A/S since August 15, 2017. He has previously been Senior Vice President, Head of North America Operations, President of Novo Nordisk Inc. at Novo Nordisk A/S since March 1, 2017. He has previously been Senior Vice President for Market Access, Novo Nordisk Inc. He joined the company in 2011 as senior director, Managed Markets. He came from GlaxoSmithKline where he was senior director of Payer Marketing. Prior to GSK, Doug Langa spent the majority of his career at Johnson & Johnson, where he held various roles of increasing responsibility within Managed Markets, Sales Leadership and Marketing. He has over 25 years of experience in the pharmaceutical and medical device industry. He graduated from Widener University and earned his MBA from Fordham University.

Camilla Sylvest

Ms. Camilla Sylvest has been appointed Executive Vice President, Commercial Strategy & Corporate Affairs at NOVO NORDISK A/S effective as of October 1, 2017. Camilla Sylvest was appointed senior vice president and general manager of Novo Nordisk's Region China in August 2015. In this role she has been responsible for the company's activities in China, Taiwan and Hong Kong. Prior to this, Camilla Sylvest has led affiliates and business areas of growing size and complexity in Europe and Asia. She started her career in Novo Nordisk in 1996, following which she had roles in headquarters and regions within pricing, health economics, marketing and sales effectiveness. She holds a M.Sc. in Economics from University of Southern Denmark and an Executive MBA from Scandinavian International Management Institute.

Henrik Wulff

Mr. Henrik Ehlers Wulff has been Executive Vice President, Product Supply at Novo Nordisk A/S since April 2015. Henrik Wulff joined Novo Nordisk in 1998 in the logistic and planning function. He was appointed senior vice president of Product Supply in 2013. He is Chair of the board of Novo Nordisk Pharmatech A/S and member of the boards of NNE A/S and Ambu A/S, all in Denmark.

Liselotte Hyveled

Ms. Liselotte Hyveled has been Director, Employee Representative at Novo Nordisk A/S since February 27, 2014. She is Member of the Research & Development Committee. She is project vice president for Novo Nordisk’s mealtime insulin projects fast-acting insulin aspart and liver-preferential mealtime insulin in Global Development. She holds Master of Science (1992) from Copenhagen University, and Master of Medical Business Strategies (2011) from Copenhagen Business School, both in Denmark.

Kasim Kutay

Anne Kverneland

Ms. Anne Marie Kverneland has been Employee Representative on the Board of Directors at Novo Nordisk A/S since November 2000. She has been Member of Board of the Novo Nordisk Foundation since 2014. She joined the Company in July 1981. She is Laboratory Technician and full-time union representative. She has a degree in Medical Laboratory Technology from Koebenhavns Universitet (Copenhagen University Hospital) in Denmark from 1980.

Helge Lund

Mr. Helge Lund has been Director of Novo Nordisk A/S since March 23, 2017. He was previously Independent Director of the Company from March 20, 2014 till March 19, 2015. He formerly served as CEO of Statoil ASA, Norway. He has been Chief executive officer of BG Group, UK, with effect from March 2, 2015. He has executive and board experience in large multinational companies headquartered in Scandinavia within regulated markets, and financial knowledge. He holds Master of Arts in Economics (1987) from the Norwegian School of Economics & Business Administration (NHH) and MBA from INSEAD (1991), France.

Stig Stroebaek

Mr. Stig Stroebaek has been Employee Representative on the Board of Directors at Novo Nordisk A/S since 1998. He has been Member of the Audit Committee of the Company since April 2013. He joined the Company in 1992 as Electrician. He is full-time union representative. Mr. Stroebaek is Qualified Electrician and holds a diploma in further training for Members of the Boards of Directors from the Danish Employees’ Capital Pension Fund (LD) from 2003.

Soeren Thuesen Pedersen

Mr. Soeren Thuesen Pedersen has been Employee Representative on the Board of Directors at Novo Nordisk A/S since March 2006. He is Member of the Nomination Committee. He joined the Company in January 1994. He works as External Affairs Director in Quality Intelligence in the Company. He is Member of the Boards of HOFOR A/S, HOFOR Forsyning Holding PS, HOFOR Forsyning Komplementar A/S and HOFOR Forsyning A/S (Copenhagen Utilities). He graduated with a Bachelor of Science degree in Chemical Engineering from Danmarks Ingenioerakademi, currently part of Danmarks Tekniske Univeristet in 1988.

Brian Daniels

Dr. Brian Daniels, M.D. has been Independent Director at Novo Nordisk A/S since March 18, 2016. He is Member of the Research & Development Committee. He is Senior Advisor with the Boston Consulting Group and venture partner with 5AM Venture Management, LLC, both in the United States. He has experience in clinical development, medical affairs and corporate strategy across a broad range of therapeutics areas within the pharmaceutical industry, especially in the US. He holds MD (1987) from Washington University, St. Louis, US, Bachelor of Science in Life Sciences (1981) and MA in Metabolism and Nutritional Biochemistry (1981), both from Massachusetts Institute of Technology, Cambridge, US.

Sylvie Gregoire

Dr. Sylvie L. Gregoire, Ph.D. has been Independent Director of Novo Nordisk A/S since March 19, 2015. She has also been Member of the Audit Committee since 2015 and serves as Member of the Research & Development Committee. She was President of Human Genetic Therapies, Shire plc, US and Switzerland, from 2007 to 2013. She is Member of the boards of Galenica AG and Perkin Elmer Inc., as well as Chairman of Corvidia Therapeutics Inc. and Executive Chair of Metriopharm. She has knowledge of the regulatory environment in both the US and the EU, having experience of all phases of the product life cycle, including discovery, registration, pre-launch and managing the life cycle while on the market. In addition, she has financial insight from i.a. P&L responsibility. She holds Pharmacy Doctorate degree (1986) from the State University of NY at Buffalo, US, BA in Pharmacy (1984) from Laval University, Canada, and Science College degree (1980) from Seminaire de Sherbrooke, Canada.

Liz Hewitt

Ms. Liz Hewitt has been Independent Member of the Board of Directors of Novo Nordisk A/S since March 21, 2012. She has been Chairman of the Company's Audit Committee since 2015 and Member of the Nomination Committee since April 2013. She was previously Group Director Corporate Affairs of Smith & Nephew plc from 2004 until 2011 and was involved at a senior level in all aspects of the business, including membership of Risk Committee of the company. From 1986 until 2004, she held a number of roles at 3i Group plc, from investing and syndicating private equity transactions to running the internal consultancy team, culminating her role as Director Corporate Affairs, when she was a Member of Risk Committee and a Trustee of the 3i Charitable Foundation. She qualified with Andersen & Co and also worked as a private equity investor for Citicorp Venture Capital (currently CVC) and Gartmore Investment Management Ltd. She serves as Member of the Board and Chair of Audit Committee of Savills plc. She is also Board Member and Chair of Nomination Committee of Melrose Industries plc and External Member and Chair of the Audit Committee of the House of Lords Commission, the United Kingdom. She has experience within the field of medical devices, financial knowledge and knowledge of how international companies operate. She holds a Bachelor of Science degree with honors in Economics from University College London from 1977 and became Chartered Accountant FCA from the Institute of Chartered Accountants in 1982.

Peter Hugreffe Ankersen